2009欧洲慢性乙型肝炎治疗指南解读

A clinical interpretation of 2009 EASL guidelines on chronic hepatitis B treatment

随着新核苷(酸)类似物陆续上市,慢性乙型肝炎(乙肝)抗病毒治疗经验不断积累,但耐药问题也日益突出,核苷(酸)类似物抗HBV的个体化方案、疗程、终点及治疗中耐药的防治已受到广泛关注。为此,欧洲肝病学会依据循证医学原则更新了慢性乙肝诊治指南,使其更具灵活性和实用性。本文简要回顾对比新指南内容,并结合临床实践对推荐意见进行分析,以促进慢性乙肝诊治的规范化。

With the availality of new nucleotides （acid） analogues, the experience of anti-virus treatment has been continuously enriched. However, the problem of drug resistance becomes increasingly significant and the concern of individualized strategies, duration and endpoints of therapy as well as drug-resistance prevention for nucleoside （acid） analogues treatment has become a hot issue. Thus, the European Association for the Study of the Liver updated their guideline on diagnosis and treatment of chronic hepatitis B based on the principles of evidencebased medicine,so as to make it more flexible and practical. We briefly review and compare the updated content of this new guideline, and make analysis combined with the clinical practice, so as to promote the standardization of diagnosis and treatment of chronic hepatitis B.